MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway

AEG-1 is associated with clinical outcome in neuroblastoma patients

(2017) Hai Yan Liu et al.   Cancer Biomarkers

Retraction Note to: Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

(2014) D Tural et al.   BRITISH JOURNAL OF CANCER

MTDH Mediates Estrogen-Independent Growth and Tamoxifen Resistance by Down-Regulating PTEN in MCF-7 Breast Cancer Cells

(2014) Chunyuan Xu et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes

(2013) Cathy B. Moelans et al.   CANCER LETTERS

Molecular determinants of trastuzumab efficacy: What is their clinical relevance?

(2013) Pradip De et al.   CANCER TREATMENT REVIEWS

A systematic review of dual targeting in HER2-positive breast cancer

(2013) Iben Kümler et al.   CANCER TREATMENT REVIEWS

The multiple layers of non-genetic regulation of PTEN tumour suppressor activity

(2013) Nádia C. Correia et al.   EUROPEAN JOURNAL OF CANCER

The Oncogene Metadherin Modulates the Apoptotic Pathway Based on the Tumor Necrosis Factor Superfamily Member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in Breast Cancer

(2013) Ning Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Renoprotective Role of Fenoldopam Pretreatment Through Hypoxia-Inducible Factor-1alpha and Heme Oxygenase-1 Expressions in Rat Kidney Transplantation

(2013) X. Yi et al.   TRANSPLANTATION PROCEEDINGS

Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer

(2012) M. S. N. Mohd Sharial et al.   ANNALS OF ONCOLOGY

Pertuzumab: new hope for patients with HER2-positive breast cancer

(2012) M. Capelan et al.   ANNALS OF ONCOLOGY

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer

(2012) R Y Tsang et al.   BRITISH JOURNAL OF CANCER

The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients

(2012) Nikola Tanic et al.   CANCER BIOLOGY & THERAPY

Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors

(2012) A. Chakrabarty et al.   CANCER RESEARCH

Self-Deprotonation and Colorization of 1,3-Bis(dicyanomethylidene)indan in Polar Media: A Facile Route to a Minimal Polymethine Dye for NIR Fluorescence Imaging

(2012) Jeongyun Heo et al.   CHEMISTRY-A EUROPEAN JOURNAL

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

(2012) C. Garcia-Garcia et al.   CLINICAL CANCER RESEARCH

Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer

(2012) A Ward et al.   ONCOGENE

Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer

(2012) Eriko Tokunaga et al.   Breast Cancer

Identification of Staphylococcal Nuclease Domain-containing 1 (SND1) as a Metadherin-interacting Protein with Metastasis-promoting Functions

(2011) Mario Andres Blanco et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Up-regulation ofmiR-21Mediates Resistance to Trastuzumab Therapy for Breast Cancer

(2011) Chang Gong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Treatment of HER2-positive breast cancer: current status and future perspectives

(2011) Carlos L. Arteaga et al.   Nature Reviews Clinical Oncology

Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology

(2011) Byoung Kwon Yoo et al.   PHARMACOLOGY & THERAPEUTICS

Knockdown of MTDH Sensitizes Endometrial Cancer Cells to Cell Death Induction by Death Receptor Ligand TRAIL and HDAC Inhibitor LBH589 Co-Treatment

(2011) Xiangbing Meng et al.   PLoS One

FOXO1A Is a Target for HER2-Overexpressing Breast Tumors

(2010) Y. Wu et al.   CANCER RESEARCH

Immunohistochemical analysis of Metadherin in proliferative and cancerous breast tissue

(2010) Peng Su et al.   Diagnostic Pathology

Significance of aeg-1 expression in correlation with vegf, microvessel density and clinicopathological characteristics in triple-negative breast cancer

(2010) Cong Li et al.   JOURNAL OF SURGICAL ONCOLOGY

MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer

(2009) Guohong Hu et al.   CANCER CELL

Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1

(2009) J Li et al.   ONCOGENE

Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis

(2009) Luni Emdad et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of genes conferring resistance to 5-fluorouracil

(2009) B. K. Yoo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Astrocyte Elevated Gene-1 is a Novel Prognostic Marker for Breast Cancer Progression and Overall Patient Survival

(2008) J. Li et al.   CLINICAL CANCER RESEARCH

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY